LY 243062

Drug Profile

LY 243062

Latest Information Update: 03 May 1995

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Anti-inflammatories; Osteoporosis therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Postmenopausal osteoporosis
  • Discontinued Inflammation

Most Recent Events

  • 03 May 1995 This profile is new.
  • 03 May 1995 No-Development-Reported for Postmenopausal osteoporosis in USA (Unknown route)
  • 03 May 1995 Discontinued-Preclinical for Inflammation in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top